Physician profile
Timothy Allen
NPI 1093203184
$3,358.45
in general payments reported to CMS, 2019-2025
17 companies · $872 in 2025
The $872 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $408 · 2024: $2,078 · 2025: $872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,278 · Education: $80.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,277.57 |
| Education | $80.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $629.34 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $462.01 | 2023-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $401.61 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $359.16 | 2023-2025 | Tremfya, Simponi Aria, Stelara |
| Abbvie INC. | $355.48 | 2023-2025 | Rinvoq |
| Pfizer INC. | $223.84 | 2024-2025 | |
| Incyte Corporation | $206.86 | 2023-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $179.66 | 2023-2025 | Ilumya, Absorica Ld, Winlevi |
| Genzyme Corporation | $118.66 | 2023-2024 | |
| Amgen INC. | $112.92 | 2024-2025 | Otezla, Otezla |
| Ucb, INC. | $88.87 | 2024-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $75.65 | 2023-2024 | Siliq, Jublia, Arazlo |
| Botanix Sb INC | $44.43 | 2025 | Sofdra |
| E.R. Squibb & Sons, L.L.C. | $34.30 | 2024 | Sotyktu |
| Galderma Laboratories, L.P. | $29.84 | 2025 | Nemluvio |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $26.99 | 2024 | Vtama |
| Mayne Pharma Commercial LLC | $8.83 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.